Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: Review of preclinical science and recent clinical trials

Robert Jackson, Orlando W Gomez-Marin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pirfenidone is a pyridine-derived, double-ringed molecule that has a number of biologic effects including anti-inflammatory and anti fibrotic properties in rodent models of acute lung injury and fibrosis, in addition to scavenging reactive oxygen species. These effects are clinically relevant, because idiopathic pulmonary fibrosis (IPF) is a progressive and increasingly prevalent disease characterized by diffuse lung scarring due to alveolar epithelial cell injury, which typically leads to death 3-5 years after diagnosis. No proven therapy for IPF exists, and many IPF patients eventually require lung transplantation, making the need for pharmacologic therapy great. Pirfenidone is rapidly distributed in body water and metabolized by the liver. Several clinical trials have tested pirfenidone in patients with IPF and found it well-tolerated with acceptable side effects. Pirfenidone in clinical trials has been found to improve progression-free survival and pulmonary function of IPF patients. Although the specific mechanism accounting for its benefits is not known, pirfenidone decreases collagen synthesis and fibroblast proliferation, and it may down-regulate inflammation by virtue of its effects on mitogen-activated protein kinases. Pirfenidone has gained regulatory approval for marketing in Japan and in the European Union. It could prove to be a useful therapeutic agent for patients with IPF.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalTransplant Research and Risk Management
Volume3
DOIs
StatePublished - Dec 1 2011

Fingerprint

Fibrosis
Idiopathic Pulmonary Fibrosis
Clinical Trials
Lung
Therapeutics
Therapy
Alveolar Epithelial Cells
Lung Transplantation
Reactive Oxygen Species
Body Water
Acute Lung Injury
Proxy
Protein Kinase
European Union
Inflammation
Transplantation
Mitogen-Activated Protein Kinases
Marketing
Collagen
Fibroblasts

Keywords

  • Idiopathic pulmonary fibrosis
  • Pirfenidone
  • Redox signaling

ASJC Scopus subject areas

  • Transplantation
  • Statistics, Probability and Uncertainty

Cite this

@article{ee368b88f15248fc977234944b7375c1,
title = "Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: Review of preclinical science and recent clinical trials",
abstract = "Pirfenidone is a pyridine-derived, double-ringed molecule that has a number of biologic effects including anti-inflammatory and anti fibrotic properties in rodent models of acute lung injury and fibrosis, in addition to scavenging reactive oxygen species. These effects are clinically relevant, because idiopathic pulmonary fibrosis (IPF) is a progressive and increasingly prevalent disease characterized by diffuse lung scarring due to alveolar epithelial cell injury, which typically leads to death 3-5 years after diagnosis. No proven therapy for IPF exists, and many IPF patients eventually require lung transplantation, making the need for pharmacologic therapy great. Pirfenidone is rapidly distributed in body water and metabolized by the liver. Several clinical trials have tested pirfenidone in patients with IPF and found it well-tolerated with acceptable side effects. Pirfenidone in clinical trials has been found to improve progression-free survival and pulmonary function of IPF patients. Although the specific mechanism accounting for its benefits is not known, pirfenidone decreases collagen synthesis and fibroblast proliferation, and it may down-regulate inflammation by virtue of its effects on mitogen-activated protein kinases. Pirfenidone has gained regulatory approval for marketing in Japan and in the European Union. It could prove to be a useful therapeutic agent for patients with IPF.",
keywords = "Idiopathic pulmonary fibrosis, Pirfenidone, Redox signaling",
author = "Robert Jackson and Gomez-Marin, {Orlando W}",
year = "2011",
month = "12",
day = "1",
doi = "10.2147/TRRM.S16205",
language = "English",
volume = "3",
pages = "55--63",
journal = "Transplant Research and Risk Management",
issn = "1179-1616",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis

T2 - Review of preclinical science and recent clinical trials

AU - Jackson, Robert

AU - Gomez-Marin, Orlando W

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Pirfenidone is a pyridine-derived, double-ringed molecule that has a number of biologic effects including anti-inflammatory and anti fibrotic properties in rodent models of acute lung injury and fibrosis, in addition to scavenging reactive oxygen species. These effects are clinically relevant, because idiopathic pulmonary fibrosis (IPF) is a progressive and increasingly prevalent disease characterized by diffuse lung scarring due to alveolar epithelial cell injury, which typically leads to death 3-5 years after diagnosis. No proven therapy for IPF exists, and many IPF patients eventually require lung transplantation, making the need for pharmacologic therapy great. Pirfenidone is rapidly distributed in body water and metabolized by the liver. Several clinical trials have tested pirfenidone in patients with IPF and found it well-tolerated with acceptable side effects. Pirfenidone in clinical trials has been found to improve progression-free survival and pulmonary function of IPF patients. Although the specific mechanism accounting for its benefits is not known, pirfenidone decreases collagen synthesis and fibroblast proliferation, and it may down-regulate inflammation by virtue of its effects on mitogen-activated protein kinases. Pirfenidone has gained regulatory approval for marketing in Japan and in the European Union. It could prove to be a useful therapeutic agent for patients with IPF.

AB - Pirfenidone is a pyridine-derived, double-ringed molecule that has a number of biologic effects including anti-inflammatory and anti fibrotic properties in rodent models of acute lung injury and fibrosis, in addition to scavenging reactive oxygen species. These effects are clinically relevant, because idiopathic pulmonary fibrosis (IPF) is a progressive and increasingly prevalent disease characterized by diffuse lung scarring due to alveolar epithelial cell injury, which typically leads to death 3-5 years after diagnosis. No proven therapy for IPF exists, and many IPF patients eventually require lung transplantation, making the need for pharmacologic therapy great. Pirfenidone is rapidly distributed in body water and metabolized by the liver. Several clinical trials have tested pirfenidone in patients with IPF and found it well-tolerated with acceptable side effects. Pirfenidone in clinical trials has been found to improve progression-free survival and pulmonary function of IPF patients. Although the specific mechanism accounting for its benefits is not known, pirfenidone decreases collagen synthesis and fibroblast proliferation, and it may down-regulate inflammation by virtue of its effects on mitogen-activated protein kinases. Pirfenidone has gained regulatory approval for marketing in Japan and in the European Union. It could prove to be a useful therapeutic agent for patients with IPF.

KW - Idiopathic pulmonary fibrosis

KW - Pirfenidone

KW - Redox signaling

UR - http://www.scopus.com/inward/record.url?scp=80052615769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052615769&partnerID=8YFLogxK

U2 - 10.2147/TRRM.S16205

DO - 10.2147/TRRM.S16205

M3 - Article

AN - SCOPUS:80052615769

VL - 3

SP - 55

EP - 63

JO - Transplant Research and Risk Management

JF - Transplant Research and Risk Management

SN - 1179-1616

ER -